MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Home・Elenco Azioni・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Chiusa

SettoreSettore sanitario

21.46 0.14

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.45

Massimo

21.47

Metriche Chiave
By Trading Economics
Entrata	-1.6M -21M
Vendite	14M 54M
Margine di Profitto	-39.611
Dipendenti	178
EBITDA	-3.8M -23M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-2.71% downside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1B 2.2B
Apertura precedente	21.32
Chiusura precedente	21.46

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

6.26 / 7.47 Supporto e resistenza

Day One Biopharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9 apr 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 apr 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 apr 2026, 23:14 UTC

Discorsi di Mercato

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 apr 2026, 23:14 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

9 apr 2026, 23:07 UTC

Discorsi di Mercato

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 apr 2026, 22:54 UTC

Discorsi di Mercato

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 apr 2026, 22:31 UTC

Principali Notizie su Eventi

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 apr 2026, 22:31 UTC

Principali Notizie su Eventi

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 apr 2026, 20:57 UTC

Principali Notizie su Eventi

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 apr 2026, 20:55 UTC

Utili

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 apr 2026, 20:55 UTC

Utili

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 apr 2026, 20:55 UTC

Utili

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 apr 2026, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

9 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 apr 2026, 20:40 UTC

Acquisizioni, Fusioni, Takeovers

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 apr 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 apr 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 apr 2026, 20:25 UTC

Acquisizioni, Fusioni, Takeovers

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 apr 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 apr 2026, 19:30 UTC

Principali Notizie su Eventi

How Digital Currencies Have Helped Iran -- WSJ

Confronto tra pari

Modifica del prezzo

Day One Biopharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

-2.71% in calo

Previsioni per 12 mesi

Media 20.86 USD -2.71%

Alto 21.5 USD

Basso 17 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

6.26 / 7.47Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.